Physician profile
David Mintell
NPI 1366453243
$1,872.50
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,873.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $139.00 | 2019 | |
| Glaxosmithkline, LLC. | $129.25 | 2019 | |
| Allergan, INC. | $125.10 | 2019 | |
| Novo Nordisk INC | $123.41 | 2019 | |
| Merck Sharp & Dohme LLC | $115.35 | 2019 | |
| Lilly USA, LLC | $109.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.92 | 2019 | |
| Pfizer INC. | $86.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $78.49 | 2019 | |
| Mdd US Operations, LLC | $64.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $64.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.61 | 2019 | |
| Scilex Pharmaceuticals INC. | $62.12 | 2019 | |
| Neurocrine Biosciences, INC. | $52.57 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $49.63 | 2019 | |
| Astellas Pharma US INC | $45.88 | 2019 | |
| Celgene Corporation | $45.79 | 2019 | |
| Abbvie INC. | $45.18 | 2019 | |
| Radius Health, INC. | $44.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $43.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $31.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.58 | 2019 | |
| Amarin Pharma, INC. | $29.64 | 2019 | |
| Aytu Biopharma, INC. | $17.21 | 2019 | |
| Lundbeck LLC | $14.62 | 2019 | |
| Daiichi Sankyo INC. | $13.76 | 2019 | |
| Metuchen Pharmaceuticals | $11.77 | 2019 | |
| Pacira Therapeutics, INC. | $11.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mintell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.